We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

AC Immune's robust pipeline

Our robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer™ technology platforms.

Crenezumab
(anti-Abeta antibody)
AD treatment
Abeta
Phase 3
Biologics
Prevention trial (API-ADAD) (Colombian population)
AD prevention
Abeta
Phase 2
Biologics
ACI-24 (anti-Abeta vaccine)
AD treatment
Abeta
Phase 2
Biologics
ACI-35 (anti-pTau vaccine)
AD treatment
Tau
Phase 1
Biologics
Anti-Tau antibody
AD treatment
Tau
Phase 2
Biologics
Morphomer Tau (Tau inhibitor, small molecule)
AD treatment
Tau
Pre-clin.
Small molecules
ACI-24 (anti-Abeta vaccine)
Down syndrome*
Abeta
Phase 1
Biologics
Morphomer Abeta (Abeta inhibitor, small molecule)
Glaucoma
Abeta
Pre-clin.
Small molecules
Morphomer a-syn (a-synuclein inhibitor, small molecule)
Parkinson's
a-synuclein
Discovery
Small molecules
Anti a–syn antibody
a-synuclein
Discovery
Biologics
Anti TDP-43 antibody
TDP-43
Discovery
Biologics
Tau-PET imaging agent
AD and PSP**
Tau
Phase 2
Diagnostics
In-vitro diagnostics (Abeta/Tau)
AD
Abeta/Tau
Pre-clin.
Diagnostics
a-syn-PET imaging agent
Parkinson's
a-synuclein
Pre-clin.
Diagnostics